Pilot Study of Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 10 Aug 2018
At a glance
- Drugs Dolutegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lamivudine/tenofovir-disoproxil-fumarate (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms TRANSViiV
- 01 Aug 2018 Planned End Date changed from 1 Dec 2017 to 1 Jul 2019.
- 01 Aug 2018 Planned primary completion date changed from 1 Oct 2017 to 1 May 2019.
- 01 Aug 2018 Status changed from recruiting to active, no longer recruiting.